News
Investor's Business Daily on MSN14d
Novartis Has A Slight Edge On Travere — Why Analysts Aren't WorriedNovartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.
Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...
The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...
The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...
Novartis (NVS) “announced the FDA has granted accelerated approval for Vanrafia, or atrasentan, a potent and selective endothelin A receptor ...
Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...
As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are navigating ...
Su principio activo, atrasentan, ha sido desarrollado por la compañía estadounidense Chinook Therapeutics adquirida por Novartis en 2023 por 3.200 millones de dólares. 'Vanrafia' está indicado ...
NEW HYDE PARK, N.Y., April 07, 2025 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia™ (atrasentan), for the reduction of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback